Atropine (Atropine)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceAtropineAtropine
Similar drugsTo uncover
  • Atropine
    drops d / eye 
    MOSCOW ENDOCRINE FACTORY, FSUE     Russia
  • Atropine
    solution for injections 
    FARMZASCHITA NPC, FSUE     Russia
  • Atropin Nova
    solution for injections 
    JODAS EKSPOIM, LLC     Russia
  • Atropine sulfate
    solution for injections 
    DALHIMFARM, OJSC     Russia
  • Atropine sulfate
    solution for injections 
    EXPERIMENTAL FACTORY ГНЦЛС, ООО     Ukraine
    • Dosage form: & nbspeye drops
    Composition:

    Composition per ml:

    Active substance:

    Atropine sulfate in terms of dry matter - 10 mg

    Excipients:

    Sodium Chloride 7.8 mg

    sodium disulfite (sodium metabisulphite) - 0.1 mg

    water for injection up to 1 ml.

    Description:Transparent colorless or slightly colored liquid.
    Pharmacotherapeutic group:M-holinoblokator
    ATX: & nbsp

    A.03.B.A   Alkaloids belladonna, tertiary amines

    A.03.B.A.01   Atropine

    Pharmacodynamics:

    The alkaloid contained in the plants of the Solanaceae family, the m-holino blockerreceptors, binds to the same degree with m1, m2, them3 - subtypes muscarinic receptors. Affects both central and peripheral m-cholinergic receptors. There is also (although much weaker) on - n -cholinergic receptors. It dilates the pupil, complicates the outflow of intraocular fluid, raises intraocular pressure, causes paralysis of accommodation.

    The pupil dilated with atropine practically does not taper at instillation holinomimetikov. The maximum dilatation of the pupil occurs in 30-40 min after instillation, disappears after 7-10 days.

    Pharmacokinetics:Well absorbed through the conjunctiva.
    Indications:To expand the pupil and achieve paralysis of accommodation: determining the true refraction of the eye, examination of the fundus; creation, functional rest in inflammatory diseases of the eye (including iritis, iridocyclitis, choroiditis, keratitis), with eye injuries, embolism and spasm of the central artery of the retina.
    Contraindications:Hypersensitivity to the components of the drug, zakratougolnaya glaucoma (including suspicion of it), keratoconus. Anterior and posterior synechia; children under 7 years.
    Carefully:Arrhythmias, chronic heart failure, ischemic heart disease, mitral stenosis, reflux esophagitis, hepatic and / or renal failure, severe urinary retention with prostatic hyperplasia, intestinal atony, obstructive bowel disease, paralytic ileus, toxic megacolon, ulcerative colitis,hernia of the esophageal opening of the diaphragm, hyperthermia, hypertension, hyperthyroidism, age over 40 (risk of undiagnosed glaucoma), myasthenia gravis.
    Pregnancy and lactation:Atropine penetrates the placental barrier. It is found in breast milk in trace concentrations. Adequate and strictly controlled clinical studies of the safety of atropine during pregnancy have not been conducted. It is allowed to use the drug during pregnancy and breastfeeding, if the expected benefit to the mother exceeds the potential risk to the fetus and the baby.
    Dosing and Administration:

    Locally. Instilled in 1-2 drops 1 % solution in the eye, the frequency of application - up to 3 times with an interval of 5-6 hours. The drug is used for 1-2 drops of 1% solution in the form of instillations in the conjunctival sac of the eye. Multiplicity of application up to 3 times with an interval of 5-6 hours.

    Side effects:

    Local: transient tingling and increased intraocular pressure; with long-term use - hyperemia of the skin of the eyelids, hyperemia and edema of the conjunctiva, eyelids and the eyeball, photophobia; contact dermatitis; toxic systemic reactions to atropine in young children and very old people (instillation of 1 drop of 1% of 1-atropine sulfate to children not only causes mydriasis and cycloplegia, but can also lead to hyperthermia, dry mouth).

    Systemic: dry mouth, tachycardia, intestinal atony, constipation, urine retention, xerostomia, atony of the bladder, headache, dizziness, impaired tactile perception.

    If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, tell your doctor!

    Overdose:

    When using atropine should be observed, caution in dosage and take into account the possibility of increased individual sensitivity of patients. Overdose can cause dry mouth, dilated pupils, disruption of accommodation, tachycardia, dizziness. However, there is no accurate data on the overdose of atropine in its local application.

    Interaction:

    Anti-asthma, potassium chloride - increased toxic effects of these drugs in connection with the possible slowdown of the passage through the gastrointestinal tract.

    The action of atropine is enhanced by sympathomimetics, m-cholinoblockers, and agents possessing m-cholinoblocking properties, weaken m-cholinomimetics. The likelihood of developing systemic adverse reactions increases tricyclic antidepressants, phenothiazines, amantadine, quinidine, antihistamines and other drugs with m-cholinoblocking properties.

    Procainamide enhances the m-cholinoblocking effect of atropine.

    With simultaneous application with phenylephrine, it is possible to increase blood pressure. Under the influence of guanethidine, hypoxecretory action may decrease atropine. Nitrates increase the likelihood of increased intraocular pressure. Atropine reduces the concentration of levodopa in the blood plasma.

    Special instructions:

    Before applying the drug, it is necessary to remove soft contact lenses.

    During the instillation of drops into the conjunctival sac to reduce the risk of developing a systemic side effect, it is recommended to lightly press the finger onto the projection area of ​​lacrimal sacs at the inner corner of the eye within 1-2 min after instillation to exclude the absorption of the nasal mucosa preparation and increased side effects.

    When instillation solution in the eye should be pressed lower tear point in avoidance of solution in the nasopharynx.

    The intensely pigmented iris is more resistant to dilatation, in order to achieve the effect, it is necessary to increase the concentration or frequency of the injections, so you should be careful not to overdose mydriatic.

    Pupil dilatation can provoke an acute attack of glaucoma in patients with glaucoma, people over 60 years of age and people with hypermetropia, predisposed to glaucoma due to the fact that they have a shallow anterior chamber.

    When used by persons over 65 years of age, there is a possibility of an increase in eye pressure.

    The drug is limited to use at an elevated body temperature (possibly further increase due to suppression of sweat glands activity), children with brain damage, infantile cerebral palsy, patients with Down's syndrome (reaction to m-holinoblockers increases) and albinism.
    Effect on the ability to drive transp. cf. and fur:

    It is necessary to warn patients that driving for at least 2 hours after the study is prohibited!

    During the application it is necessary to refrain from driving motor vehicles and occupations, potentially hazardous activities requiring increased concentration of attention, speed of psychomotor reactions and good vision.
    Form release / dosage:Eye drops 1%.
    Packaging:

    1 bottle complete with a sterile cap-dropper and instruction on the use of the drug is placed in a pack of cardboard. 5 vials into the contour cell package.

    1 circuit cell package complete with 5 sterile droppers and instructions for use of the drug is placed in a pack of cardboard.

    30 contour mesh packages complete with sterile dropper caps (by the number of bottles) and 15 instructions for use, the drug is placed in a box of cardboard or in a box of corrugated cardboard (for hospitals).
    Storage conditions:

    In the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LS-001248
    Date of registration:03.08.2011
    Expiration Date:Unlimited
    The owner of the registration certificate:MOSCOW ENDOCRINE FACTORY, FSUE MOSCOW ENDOCRINE FACTORY, FSUE Russia
    Manufacturer: & nbsp
    Information update date: & nbsp04.10.2017
    Illustrated instructions
      Instructions
      Up